Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: A systematic review and meta-analysis

BMC Medicine

Volumn 14, Issue 1, 2016, Pages

  Gupta Wright, Ankur ^a,b   Peters, Jurgens A ^a   Flach, Clare ^a   Lawn, Stephen D ^a,c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF MALAWI   (Malawi)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

HIV; LAM; Lipoarabinomannan; Mortality; Systematic review; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; LIPOARABINOMANNAN; TUBERCULOSTATIC AGENT; BIOLOGICAL MARKER; LIPOPOLYSACCHARIDE;

ADULT; AFRICA SOUTH OF THE SAHARA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FATALITY; FOLLOW UP; GOLD STANDARD; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID ANALYSIS; LIPOARABINOMANNAN URINE LEVEL; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; NONHUMAN; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TUBERCULOSIS; URINALYSIS; URINE LEVEL; COMPLICATION; FEMALE; MALE; PROSPECTIVE STUDY; URINE;

ADULT; AFRICA SOUTH OF THE SAHARA; BIOMARKERS; FEMALE; HIV INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS;

EID: 84961626325     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-016-0603-9     Document Type: Article

References (56)

1. World Health Organization. Global tuberculosis report 2015. Geneva: WHO; 2015.
2. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis. 2009;9:173-84. doi: 10.1016/S1473-3099(09)70043-X.
3. Elliott AM, Halwiindi B, Hayes RJ, Luo N, Tembo G, et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg. 1993;96:1-11.
4. Gilks CF, Brindle RJ, Otieno LS, Bhatt SM, Newnham RS, et al. Extrapulmonary and disseminated tuberculosis in HIV-1-seropositive patients presenting to the acute medical services in Nairobi. AIDS. 1990;4:981-5.
5. World Health Organization. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: WHO; 2014.
6. Pai M, Palamountain KM. New tuberculosis technologies: challenges for retooling and scale-up. Int J Tuberc Lung Dis. 2012;16:1281-90. doi: 10.5588/ijtld.12.0391.
7. Lin H-H, Langley I, Mwenda R, Doulla B, Egwaga S, et al. A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools. Int J Tuberc Lung Dis. 2011;15:996-1004. doi: 10.5588/ijtld.11.0062.
8. Choudhry V, Saxena RK. Detection of Mycobacterium tuberculosis antigens in urinary proteins of tuberculosis patients. Eur J Clin Microbiol Infect Dis. 2002;21:1-5.
9. Kashino SS, Pollock N, Napolitano DR, Rodrigues V, Campos-Neto A. Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clin Exp Immunol. 2008;153:56-62. doi: 10.1111/j.1365-2249.2008.03672.x.
10. Achkar JM, Lawn SD, Moosa M-YS, Wright CA, Kasprowicz VO. Adjunctive tests for diagnosis of tuberculosis: serology, ELISPOT for site-specific lymphocytes, urinary lipoarabinomannan, string test, and fine needle aspiration. J Infect Dis. 2011;204(Suppl):S1130-41. doi: 10.1093/infdis/jir450.
11. Minion J, Leung E, Talbot E, Dheda K, Pai M, et al. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J. 2011;38:1398-405. doi: 10.1183/09031936.00025711.
12. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012;12:201-9. doi: 10.1016/S1473-3099(11)70251-1.
13. Peter JG, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J. 2012;40:1211-20. doi: 10.1183/09031936.00201711.
14. Fielding KL, Charalambous S, Hoffmann CJ, Johnson S, Tlali M, et al. Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial. Trials. 2015;16:125. doi: 10.1186/s13063-015-0650-0.
15. Peter J. A Trial of the Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients (LAMRCT) NCT01770730. Available: http://clinicaltrials.gov/show/NCT01770730.
16. Lawn SD. Rapid urine-based Screening for Tuberculosis to reduce AIDS-related Mortality in hospitalized Patients in Africa (STAMP) trial. ISRCTN71603869. Available: http://www.isrctn.com/ISRCTN71603869.
17. World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV: policy. Geneva: WHO; 2015.
18. Shah M, Hanrahan CF, Wang Z, Steingart K, Lawn S, et al. Urine lateral flow lipoarabinomannan assay for diagnosing active tuberculosis in adults living with HIV. Cochrane Database Syst Rev. 2014;12:CD011420.
19. Kerkhoff AD, Wood R, Vogt M, Lawn SD. Prognostic value of a quantitative analysis of lipoarabinomannan in urine from patients with HIV-associated tuberculosis. PLoS One. 2014;9:e103285. doi: 10.1371/journal.pone.0103285.
20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-12. doi: 10.1016/j.jclinepi.2009.06.005.
21. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529-36. doi: 10.7326/0003-4819-155-8-201110180-00009.
22. Boehme C, Molokova E, Minja F, Geis S, Loscher T, et al. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans R Soc Trop Med Hyg. 2005;99:893-900. doi: 10.1016/j.trstmh.2005.04.014.
23. Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, et al. Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med. 2010;16:262-70. doi: 10.1097/MCP.0b013e328337f23a.
24. Wood R, Racow K, Bekker L-G, Middelkoop K, Vogt M, et al. Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria. BMC Infect Dis. 2012;12:47. doi: 10.1186/1471-2334-12-47.
25. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis. 2012;12:103. doi: 10.1186/1471-2334-12-103.
26. Cox JA, Lukande RL, Kalungi S, Van Marck E, Van de Vijver K, et al. Is urinary lipoarabinomannan the result of renal tuberculosis? Assessment of the renal histology in an autopsy cohort of Ugandan HIV-infected adults. PLoS One. 2015;10:e0123323. doi: 10.1371/journal.pone.0123323.
27. Lawn SD, Gupta-Wright A. Detection of lipoarabinomannan (LAM) in urine is indicative of disseminated tuberculosis with renal involvement in patients living with HIV and advanced immunodeficiency: evidence and implications. Trans R Soc Trop Med Hyg. 2016;110:180-5.
28. Manabe YC, Nonyane BA, Nakiyingi L, Mbabazi O, Lubega G, et al. Point-of-care lateral flow assays for tuberculosis and cryptococcal antigenuria predict death in HIV infected adults in Uganda. PLoS One. 2014;9:e101459. doi: 10.1371/journal.pone.0101459.
29. Nakiyingi L, Ssengooba W, Nakanjako D, Armstrong D, Holshouser M, et al. Predictors and outcomes of mycobacteremia among HIV-infected smear-negative presumptive tuberculosis patients in Uganda. BMC Infect Dis. 2015;15:1-8. doi: 10.1186/s12879-015-0812-4.
30. Nakiyingi L, Moodley VM, Manabe YC, Nicol MP, Holshouser M, et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr. 2014;66:270-9. doi: 10.1097/QAI.0000000000000151.
31. Lawn SD, Kerkhoff AD. Rapid diagnosis of TB in HIV-positive in-patients with M. tuberculosis bacteraemia in sub-Saharan Africa. Int J Tuberc Lung Dis. 2015;19:1557-9.
32. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker L-G, et al. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS. 2009;23:1875-80. doi: 10.1097/QAD.0b013e32832e05c8.
33. Namale PE, Abdullahi LH, Fine S, Kamkuemah M, Wilkinson RJ, et al. Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Future Microbiol. 2015;10:1077-99. doi: 10.2217/fmb.15.9.
34. Gupta A, Nadkarni G, Yang W-T, Chandrasekhar A, Gupte N, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One. 2011;6:e28691. doi: 10.1371/journal.pone.0028691.
35. Strohmeier GR, Fenton MJ. Roles of lipoarabinomannan in the pathogenesis of tuberculosis. Microbes Infect. 1999;1:709-17. doi: 10.1016/S1286-4579(99)80072-0.
36. Angala SK, Belardinelli JM, Huc-Claustre E, Wheat WH, Jackson M. The cell envelope glycoconjugates of Mycobacterium tuberculosis. Crit Rev Biochem Mol Biol. 2014;49:361-99. doi: 10.3109/10409238.2014.925420.
37. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2003;83:91-7.
38. Mishra AK, Driessen NN, Appelmelk BJ, Besra GS. Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosis physiology and host-pathogen interaction. FEMS Microbiol Rev. 2011;35:1126-57. doi: 10.1111/j.1574-6976.2011.00276.x.
39. Shabaana AK, Kulangara K, Semac I, Parel Y, Ilangumaran S, et al. Mycobacterial lipoarabinomannans modulate cytokine production in human T helper cells by interfering with raft/microdomain signalling. Cell Mol Life Sci. 2005;62:179-87. doi: 10.1007/s00018-004-4404-5.
40. Neyrolles O, Guilhot C. Recent advances in deciphering the contribution of Mycobacterium tuberculosis lipids to pathogenesis. Tuberculosis (Edinb). 2011;91:187-95. doi: 10.1016/j.tube.2011.01.002.
41. Joe M, Sun D, Taha H, Completo GC, Croudace JE, et al. The 5-deoxy-5-methylthio-xylofuranose residue in mycobacterial lipoarabinomannan. absolute stereochemistry, linkage position, conformation, and immunomodulatory activity. J Am Chem Soc. 2006;128:5059-72. doi: 10.1021/ja057373q.
42. Garg A, Barnes PF, Roy S, Quiroga MF, Wu S, et al. Mannose-capped lipoarabinomannan- and prostaglandin E2-dependent expansion of regulatory T cells in human Mycobacterium tuberculosis infection. Eur J Immunol. 2008;38:459-69.
43. Geijtenbeek TBH, Van Vliet SJ, Koppel EA, Sanchez-Hernandez M, Vandenbroucke-Grauls CMJE, et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med. 2003;197:7-17.
44. Fratti RA, Chua J, Vergne I, Deretic V. Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc Natl Acad Sci U S A. 2003;100:5437-42. doi: 10.1073/pnas.0737613100.
45. Fukuda T, Matsumura T, Ato M, Hamasaki M, Nishiuchi Y, et al. Critical roles for lipomannan and lipoarabinomannan in cell wall integrity of mycobacteria and pathogenesis of tuberculosis. MBio. 2013;4:e00472-12. doi: 10.1128/mBio.00472-12.
46. Briken V, Porcelli SA, Besra GS, Kremer L. Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol Microbiol. 2004;53:391-403. doi: 10.1111/j.1365-2958.2004.04183.x.
47. Shah M, Variava E, Holmes CB, Coppin A, Golub JE, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr. 2009;52:145-51. doi: 10.1097/QAI.0b013e3181b98430.
48. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Clinical significance of lipoarabinomannan (LAM) detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. AIDS. 2012;26:1635-43. doi: 10.1097/QAD.0b013e3283553685.
49. Talbot E, Munseri P, Teixeira P, Matee M, Bakari M, et al. Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS One. 2012;7:e32876. doi: 10.1371/journal.pone.0032876.
50. Peter JG, Theron G, Dheda K. Can point-of-care urine LAM strip testing for tuberculosis add value to clinical decision making in hospitalised HIV-infected persons? PLoS One. 2013;8:e54875. doi: 10.1371/journal.pone.0054875.
51. Balcha TT, Winqvist N, Sturegård E, Skogmar S, Reepalu A, et al. Detection of lipoarabinomannan in urine for identification of active tuberculosis among HIV-positive adults in Ethiopian health centres. Trop Med Int Health. 2014;19:734-42. doi: 10.1111/tmi.12308.
52. Drain PK, Gounder L, Grobler A, Sahid F, Bassett IV, et al. Urine lipoarabinomannan to monitor antituberculosis therapy response and predict mortality in an HIV-endemic region: a prospective cohort study. BMJ Open. 2015;5:e006833. doi: 10.1136/bmjopen-2014-006833.
53. Peter J, Theron G, Chanda D, Clowes P, Rachow A, et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing. BMC Infect Dis. 2015;15:262. doi: 10.1186/s12879-015-0967-z.
54. Lawn SD, Kerkhoff AD, Burton R, Vogt M, Pahlana P, et al. Systematic investigation for tuberculosis in HIV-infected patients on the first day of admission to a South African hospital: incremental diagnostic yield, accuracy and prognostic value of a urine LAM lateral-flow assay. 45th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union). Barcelona, Spain. 2014. HIV Late Breaker Oral Presentation (HIV_LB04).
55. Bjerrum S, Kenu E, Lartey M, Newman MJ, Addo KK, et al. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV-infected adults in Ghana-findings from the DETECT HIV-TB study. BMC Infect Dis. 2015;15:407. doi: 10.1186/s12879-015-1151-1.
56. Cummings MJ, O'Donnell MR. Inverting the pyramid: increasing awareness of mycobacterial sepsis in sub-Saharan Africa. Int J Tuberc Lung Dis. 2015;19:1128-34.